CRISPR-Cas9 technologyembryonic developmentgenome manipulationGenome manipulation was first made possible in the 1970s when Escherichia coli was first manipulated to produce somatostatin, a therapeutic protein, by fusing this gene to the E. coli betaゞalactosidase gene on a plasmid and transforming it...
In recent years, the RNA-programmable CRISPR/Cas9 technology of genome editing has caught the eyes of researchers and has traversed a long way in a very short period since it is an uncomplicated and effortless process. The field of biology (animal, plant and microbe) has undergone a massive ...
This technology can be used to investigate the function of a gene of interest or to correct gene mutations in cells via genome editing, paving the way for future gene therapy approaches. Improvements to the efficiency of CRISPR repair, in particular to increase the rate of gene correction and ...
and the clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) system (CRISPR/Cas) [10]. Compared with the other techniques, CRISPR/Cas9 has become a powerful technology for gene editing because of its easy construction...
- Patent covers successful integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR - Fourth patent allowance for Merck's CRISPR technology; similar patents from Australian, Canadian and European Patent Offices already received ...
Once formally granted, the Canadian patent will extend the protection of Merck's CRISPR integration technology intoNorth Americafor the first time, further strengthening the company's patent portfolio. The Australian Patent Office granted Merck its first CRISPR patent in June of ...
18 reported the use of CRISPR/Cas9 in mouse and human cells, respectively, and showed that they could edit target specific genes of mammalian cells successfully in March 2013. Then, three research teams19, 20, 21 were able to use CRISPR/Cas9 to target genes in plants and the technology ...
and we view this announcement as recognition of Merck's important contributions to the genome-editing field," saidUdit Batra, Member of the Merck Executive Board and CEO, Life Science. "This patent provides protection for our CRISPR technology, which will give scientists the...
However, as with every emerging technology, there are certain disadvantages and technical difficulties that need to be overcome, particularly for in vivo CRISPR/Cas9-based gene editing. The nature of CRISPR/Cas9-based gene editing by NHEJ-mediated indels leads to a lot of variation in the mutant...
Since its discovery, the Clustered Regularly Interspaced Short Palindromic Repeat (the CRISPR) system has been increasingly applied to therapeutic genome e